204 related articles for article (PubMed ID: 21970911)
21. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
Cole RE
Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
[TBL] [Abstract][Full Text] [Related]
22. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of a strategy for the management of accompanying osteoporosis after inpatient treatment of fragility fractures].
Bahrs C; Türk A; Eingartner C; Weise K; Rolauffs B; Stuby F
Z Orthop Unfall; 2008; 146(1):52-8. PubMed ID: 18324582
[TBL] [Abstract][Full Text] [Related]
24. [Hip Fracture--Epidemiology, Management and Liaison Service. Prevention of the secondary hip fractures utilizing the regional post-referral treatment plan].
Matsushita M
Clin Calcium; 2015 Apr; 25(4):545-50. PubMed ID: 25814015
[TBL] [Abstract][Full Text] [Related]
25. Secondary prevention of osteoporosis following fragility fractures of the distal radius in a large health maintenance organization.
Benzvi L; Gershon A; Lavi I; Wollstein R
Arch Osteoporos; 2016; 11():20. PubMed ID: 27142832
[TBL] [Abstract][Full Text] [Related]
26. [Cardiovascular disease, osteoporosis and risk of fracture].
Reyes-García R; Rozas-Moreno P; Muñoz-Torres M
Rev Clin Esp; 2012 Apr; 212(4):188-92. PubMed ID: 21798531
[TBL] [Abstract][Full Text] [Related]
27. Osteoporosis: from early fracture prevention to better bone health with strontium ranelate.
Cortet B
Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv14-9. PubMed ID: 19783589
[TBL] [Abstract][Full Text] [Related]
28. Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial.
Montori VM; Shah ND; Pencille LJ; Branda ME; Van Houten HK; Swiglo BA; Kesman RL; Tulledge-Scheitel SM; Jaeger TM; Johnson RE; Bartel GA; Melton LJ; Wermers RA
Am J Med; 2011 Jun; 124(6):549-56. PubMed ID: 21605732
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis.
Hiligsmann M; Vanoverberghe M; Neuprez A; Bruyère O; Reginster JY
Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):359-66. PubMed ID: 20715911
[TBL] [Abstract][Full Text] [Related]
30. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
Boonen S; Klemes AB; Zhou X; Lindsay R
J Am Geriatr Soc; 2010 Apr; 58(4):658-63. PubMed ID: 20345865
[TBL] [Abstract][Full Text] [Related]
32. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of a program of integrated care to reduce recurrent osteoporotic fractures.
Goltz L; Degenhardt G; Maywald U; Kirch W; Schindler C
Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):263-70. PubMed ID: 23296590
[TBL] [Abstract][Full Text] [Related]
34. [The importance of taking care of osteoporosis].
Rousière M
Presse Med; 2011 Oct; 40(10):900-9. PubMed ID: 21493035
[TBL] [Abstract][Full Text] [Related]
35. Osteosynthesis of fragility fractures.
Tarantino U; Iundusi R; Lecce D; Tempesta V; Perrone FL; Rao C; Cerocchi I; Gasbarra E
Aging Clin Exp Res; 2011 Apr; 23(2 Suppl):54-6. PubMed ID: 21970924
[TBL] [Abstract][Full Text] [Related]
36. Approach to the Patient With Bone Fracture: Making the First Fracture the Last.
Wang M; Seibel MJ
J Clin Endocrinol Metab; 2023 Nov; 108(12):3345-3352. PubMed ID: 37290052
[TBL] [Abstract][Full Text] [Related]
37. Understanding fragility fracture patients' decision-making process regarding bisphosphonate treatment.
Wozniak LA; Johnson JA; McAlister FA; Beaupre LA; Bellerose D; Rowe BH; Majumdar SR
Osteoporos Int; 2017 Jan; 28(1):219-229. PubMed ID: 27423660
[TBL] [Abstract][Full Text] [Related]
38. Adherence to osteoporosis pharmacotherapy one year after osteoporotic fracture - a Swiss trauma center secondary prevention project.
Morell S; Hemmeler C; Amsler F; Gross T
Swiss Med Wkly; 2017; 147():w14451. PubMed ID: 28695555
[TBL] [Abstract][Full Text] [Related]
39. Are hospitalized patients with fragile fractures managed properly in relation to underlying osteoporosis?
Mehrpour SR; Aghamirsalim MR; Sorbi R
J Clin Rheumatol; 2012 Apr; 18(3):122-4. PubMed ID: 22426584
[TBL] [Abstract][Full Text] [Related]
40. An Orthopaedic Surgeon Led Osteoporosis (OSLO) Model of Care reduces early recurrent fracture rates and improves treatment compliance in patients treated for osteoporotic fractures.
Ding BTK; Lim HF; Johari F; Kunnasegaran R
Osteoporos Int; 2023 Feb; 34(2):299-307. PubMed ID: 36409358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
